Much ado about nothing: methicillin-resistant Staphylococcus aureus

Area of Science:

• Infectious Diseases
• Clinical Microbiology
• Health Economics

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-resistant Staphylococcus epidermidis (MRSE) are significant pathogens.
• Gram-negative bacteria also contribute substantially to hospital-acquired infections.
• Concerns regarding MRSA/MRSE morbidity, mortality, and treatment costs are widespread.

Purpose of the Study:

• To compare morbidity, mortality, and cost factors of MRSA/MRSE infections versus gram-negative infections.
• To evaluate the economic and clinical impact of these prevalent pathogens over a four-year period.

Main Methods:

• Retrospective analysis of over 214 documented infections.
• Comparison of morbidity and mortality rates between MRSA/MRSE and gram-negative infections.
• Assessment of treatment costs and hospital stay duration for different infection types.

Main Results:

• MRSA/MRSE infections demonstrated minor morbidity and mortality rates.
• Gram-negative infections, particularly Pseudomonas aeruginosa and Escherichia coli, often required dual antimicrobial therapy, increasing costs and morbidity.
• Gram-negative infections led to 10-15 additional hospital days and higher daily antibiotic expenses ($293.40).
• MRSA/MRSE infections were 28% less costly to treat compared to gram-negative infections.

Conclusions:

• The clinical and economic burden of gram-negative infections is significantly higher than that of MRSA/MRSE infections.
• Current focus on MRSA/MRSE may be disproportionate given the comparative impact of gram-negative pathogens.
• Resource allocation and treatment strategies should consider the substantial burden of gram-negative infections.